The future of antivenoms: Oligoclonal mixtures of recombinant, human(ized) antibodies

Research output: Contribution to conferencePosterResearchpeer-review

92 Downloads (Pure)

Abstract

More than 5.5 million people are bitten by venomous snakes every year on a global basis, which leads to an estimated 125,000 deaths and 3 times as many amputations. The cornerstone of snakebite therapy remains to be parental administration of equine or ovine antisera, which are associated with severe side effects due to their heterologous nature. Additionally, cost of antivenom has been identified as one of the key voids hindering snakebite victims from receiving antivenom in sub-Saharan Africa. A widespread notion exists that investing in the development of novel antivenoms based on recombinant expression of human(ized) antibodies or antibody fragments is not commercially attractive. Here, a simple,coarse-grained economical assessment of producing modern antivenoms based on oligoclonal mixtures of humanized antibodies and antibody fragments is presented.
Original languageEnglish
Publication date2015
Number of pages1
Publication statusPublished - 2015
Externally publishedYes
Event18th World Congress of the International Society on Toxinology - The Examination Schools & The Sheldonian Theatre, Oxford, United Kingdom
Duration: 25 Sept 201530 Sept 2015
Conference number: 18

Conference

Conference18th World Congress of the International Society on Toxinology
Number18
LocationThe Examination Schools & The Sheldonian Theatre
Country/TerritoryUnited Kingdom
CityOxford
Period25/09/201530/09/2015

Fingerprint

Dive into the research topics of 'The future of antivenoms: Oligoclonal mixtures of recombinant, human(ized) antibodies'. Together they form a unique fingerprint.

Cite this